Clarity Pharmaceuticals (ASX:CU6) logged a AU$0.291 loss per share for fiscal 2026, compared with a loss of AU$0.201 a year ago, a Thursday filing showed.
For the 12 months ended June 30, revenue from ordinary activities was AU$8 million, which the Australia-listed developer of radiopharmaceutical diagnostics products said was up 68% from a year earlier.